What analysts say:
- Buy, sell, or hold?: Half of analysts think investors should stand pat on UGI while the remaining half rate the stock as a buy. Analysts like UGI better than competitor Vectren overall. Zero out of six analysts rate Vectren a buy compared to one of two for UGI. Analysts' rating of UGI has stayed constant from three months prior.
- Revenue Forecasts: On average, analysts predict $2.76 billion in revenue this quarter. That would represent a rise of 26.6% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $1.24 per share. Estimates range from $1.23 to $1.25.
What our community says:
CAPS All-Stars are strongly supporting the stock, with 95.7% giving it an "outperform" rating. Most of the community concurs with the All-Stars, with 94.9% awarding it a rating of "outperform." UGI has a bullish CAPS rating of five out of five stars that is about on par with the Fool community assessment.
A year-over-year revenue decrease last quarter snaps a streak of three consecutive quarters of revenue increases.
For all our UGI-specific analysis, including earnings and beyond, add UGI to My Watchlist.